30th Sep 2021 06:42
(Correcting headline to clarify trial is being conducted by investee Artios.)
Arix Bioscience PLC - London-based venture capital firm investing in biotech companies - Portfolio company, Artios Pharma Ltd, on Monday says first patient in Phase 1/2a study with its polymerase theta inhibitor ART4215 has been dosed. ART4215 is tumour-specific and targets DNA damage response process to treat a broad range of cancers, administered orally. Expects interim safety and tolerability data in 2022.
Artios' project was originally in-licensed from Cancer Research UK in 2016 as part of its initial formation. In April, Artios announced global research collaboration with Novartis AG to discover and validate next generation DNA damage response targets.
"The initiation of our Phase 1/2a study is an important milestone for Artios and the DNA Damage Response field in general, launching the first evaluation of a specifically designed Pol0 inhibitor in the clinic," says Artios Chief Executive Niall Martin.
Current stock price: 153.50 pence
Year-to-date change: down 30%
By Josie O'Brien; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L